BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28115358)

  • 1. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
    McKee SJ; Doff BL; Soon MS; Mattarollo SR
    Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
    Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
    Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Adrenergic Signaling Impairs Antitumor CD8
    Nissen MD; Sloan EK; Mattarollo SR
    Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
    Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
    J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
    Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
    Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
    Joseph AM; Srivastava R; Zabaleta J; Davila E
    Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8
    Buchan SL; Fallatah M; Thirdborough SM; Taraban VY; Rogel A; Thomas LJ; Penfold CA; He LZ; Curran MA; Keler T; Al-Shamkhani A
    Clin Cancer Res; 2018 May; 24(10):2383-2394. PubMed ID: 29514845
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
    PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
    Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
    Front Immunol; 2020; 11():577. PubMed ID: 32391001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
    Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
    Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
    Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
    Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
    Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses.
    Menk AV; Scharping NE; Rivadeneira DB; Calderon MJ; Watson MJ; Dunstane D; Watkins SC; Delgoffe GM
    J Exp Med; 2018 Apr; 215(4):1091-1100. PubMed ID: 29511066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
    Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
    Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.